D. Boral Capital Reaffirms “Buy” Rating for Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating reiterated by D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $46.00 price target on the biotechnology company’s stock. D. Boral Capital’s price target suggests a potential upside of 472.85% from the company’s previous close.

AVXL has been the topic of a number of other reports. Jones Trading cut shares of Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Friday, October 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Anavex Life Sciences in a research report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and set a $42.00 price target on shares of Anavex Life Sciences in a research report on Tuesday, October 7th. Finally, Wall Street Zen cut shares of Anavex Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 23rd. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $44.00.

Anavex Life Sciences Price Performance

Shares of Anavex Life Sciences stock opened at $8.03 on Wednesday. Anavex Life Sciences has a fifty-two week low of $5.87 and a fifty-two week high of $14.44. The firm has a 50 day simple moving average of $9.09 and a 200 day simple moving average of $9.36. The firm has a market cap of $689.73 million, a P/E ratio of -14.09 and a beta of 0.83.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). On average, sell-side analysts expect that Anavex Life Sciences will post -0.69 EPS for the current year.

Institutional Investors Weigh In On Anavex Life Sciences

Institutional investors have recently added to or reduced their stakes in the stock. State of Wyoming bought a new stake in Anavex Life Sciences in the 2nd quarter valued at $26,000. SBI Securities Co. Ltd. increased its position in shares of Anavex Life Sciences by 470.0% in the second quarter. SBI Securities Co. Ltd. now owns 4,879 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 4,023 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Anavex Life Sciences by 22.3% in the second quarter. Ameritas Investment Partners Inc. now owns 8,535 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 1,559 shares during the last quarter. Kovack Advisors Inc. acquired a new stake in shares of Anavex Life Sciences in the second quarter valued at about $93,000. Finally, Weaver Consulting Group acquired a new stake in shares of Anavex Life Sciences in the second quarter valued at about $94,000. 31.55% of the stock is owned by institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.